Scientists Isolate Potent Measles-Blocking Antibodies From Vaccinated Patient’s Blood Amid U.S. Resurgence

Scientists at the La Jolla Institute for Immunology isolated potent measles-blocking antibodies from the blood of a vaccinated woman, a study published May 8, 2026, in Cell Host & Microbe reported. According to study leader Erica Ollmann Saphire, the antibodies target key viral proteins and demonstrated both preventive and post-exposure treatment effects in rodent models, offering potential protection amid the U.S. measles resurgence.

The antibodies, isolated from the blood of a woman vaccinated against measles many years prior, specifically target two critical viral proteins: the fusion protein and the attachment protein known as “H,” according to the study published May 8, 2026, in Cell Host & Microbe.

These antibodies demonstrated the ability to prevent initial infection when administered before exposure to the virus and showed therapeutic effects when given within 24 to 48 hours after exposure, reducing viral loads by 500-fold in rodent models, the researchers reported.

Erica Ollmann Saphire, the study leader at the La Jolla Institute for Immunology, said the antibodies’ dual capacity for prophylaxis and post-exposure treatment offers a potential new tool for protecting vulnerable populations, including immunocompromised individuals, unvaccinated children, and infants too young to receive the measles vaccine. One specific antibody, designated 3A12, was noted to render circulating virus undetectable in the rodent model, highlighting its potency, the report stated.

The antibodies were derived from a volunteer with long-term immunity from prior vaccination, underscoring the potential of vaccine-induced antibodies to provide broad protection. Saphire emphasized that the 3D structural images of the antibodies’ binding sites provide a foundation for developing the first measles treatments effective both before and after exposure, a significant advancement amid the ongoing resurgence of measles cases in the United States.

The study’s findings align with previous research indicating that neutralizing antibodies are critical for measles protection. A 2007 study published by the American Society for Microbiology noted that while T-cell responses contribute to immunity, neutralizing antibodies are the primary defense against infection. The La Jolla Institute’s research demonstrates that vaccine-derived antibodies can match the potency of those produced by natural infection, which is known to induce lifelong immunity with high neutralizing antibody levels.

Additional context from Centers for Disease Control and Prevention (CDC) reports suggests that high levels of neutralizing antibodies, exceeding 40,000 mIU/mL, may indicate reinfection risk even in vaccinated individuals. The researchers pointed out that maternal antibodies, which typically range between neutralizing titers of 160 to 320, can interfere with the development of a neutralizing antibody response in infants, complicating early immunization efforts.

The study also highlights differences in immune responses to measles infection versus vaccination. For example, antibodies targeting the matrix protein appear only in clinical infections and not in vaccinated individuals, as noted in a 2017 publication in PMC550845. This distinction may have implications for diagnostic and treatment strategies.

Rodent model experiments demonstrated that pre-exposure prophylaxis with the antibodies fully protected against infection, while post-exposure treatment administered within 24 to 48 hours significantly reduced viral replication. These results support the potential use of antibody infusions as a complement to traditional vaccines, especially for outbreak control.

Public health officials have emphasized the importance of maintaining vaccination coverage above 90% to achieve herd immunity, as outlined in a 2012 study published in PMC13111915. The resurgence of measles in the United States has been linked to declining vaccination rates and increased transmission, underscoring the need for additional preventive measures.

Broader research into measles immunity also involves understanding the roles of B and T cell responses and immune memory. According to the CDC, avidity testing can distinguish between primary and secondary vaccine failures, which is critical for outbreak investigations such as those in detention facilities. Genotyping and IgM antibody detection remain essential tools for accurate diagnosis, as reported in a recent Spanish study.

Advances in vaccine technology, including genetically modified vaccines designed for improved delivery and immune response, are also being explored to enhance measles control efforts. The isolation of potent measles-blocking antibodies from vaccinated individuals contributes to this evolving landscape by offering potential new avenues for both prevention and treatment amid ongoing public health challenges.